Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Miniantibody) (MNAB-115)

Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Miniantibody) is a fusion protein of two scFv fragments combined with distinct specificity. One scFv of an anti-CD33 antibody variable domain is linked to another scFv of an anti-CD64 antibody variable domain by a flexible hinge region. This BsAb format has the decreased size and better penetration than conventional IgGs in the clinical diagnostics and potentially therapy. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD33 & CD64

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer

Targets

Target 1

CD33

Gene ID

945

UniProt ID

P20138

Alternative Names

CD33; CD33 molecule; Cluster of differentiation 33; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Miniantibody) (MNAB-115). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (Miniantibody) (CAT#: MNAB-115)

Specifications

Targets

Customer Reviews and Q&As